ClinicalTrials.Veeva

Menu

A Novel Imaging Modality to Evaluate Radiation-Induced Uterine Injury

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status

Enrolling

Conditions

Uterine Injury

Treatments

Diagnostic Test: MRI, SWE, and US evaluation

Study type

Interventional

Funder types

Other

Identifiers

NCT06518174
21-5074.cc

Details and patient eligibility

About

The goal of this pilot study is to assess the ability of a new imaging modality, shear-wave-elastography (SWE) and magnetic resonance imaging (MRI) to identify radiation-induced uterine injury (RIUI). The investigator will recruit female patients treated before 40 years with pelvic radiation (PRT) at least 12 months prior to study initiation.

Full description

The investigator will recruit female patients treated before 40 years with pelvic radiation (PRT) at least 12 months prior to study initiation.12 months is selected to increase the occurrence of uterine fibrosis. The investigator will perform transabdominal standard B-mode and Doppler US, SWE and pelvic MRI and characterize uterine parameters. The B-mode and Doppler US will be referred to collectively as US. This will provide essential information to design an intervention trial of a novel therapeutic approach to the treatment of radiation-induced uterine damage. The overall objective of the study will be achieved through the following specific aims:

Aim 1: Assess the feasibility of SWE and pelvic MRI to identify and characterize uterine fibrosis. Hypothesis: A grid map sampling of the uterus will indicate feasibility of SWE and pelvic MRI to detect and characterize uterine fibrosis.

Approach: SWE and MRI will be performed at time of study recruitment. US procedures will be transabdominal. When possible, and with participant consent, transvaginal US will also be performed. MRI images will also be sampled from existing pretreatment studies performed as standard of care.

Perform SWE and MRI sampling of the uterus from fundus to lower uterine segment at two locations each from the upper, mid, and lower thirds of the uterus (six grid sample locations).

Obtain five measurements at each location to evaluate for the presence and degree of fibrosis:

  1. Assess the relationship between SWE measurements in kiloPascals (kPa) and each MRI parameter among cases at the post-treatment timepoint.
  2. Assess the relationship between SWE measurements and each MRI parameter in kPa among controls at one random timepoint.
  3. Evaluate differences in kPa between cases and controls according to SWE at the post-treatment timepoint. The imaging study will be considered feasible if at least 85% (e.g., ≥15/17) of all enrolled cases achieve the diagnosability criteria by SWE, defined as having the interquartile range to median ratio (IQR/M) of the measurements (kPa) <=30% at any of the six locations.

Aim 2: Characterize uterine parameters after PRT. Hypothesis: Patients treated with PRT for colorectal/anal cancer will have decreased uterine volume and increased arterial resistive indices (blood flow) on US.

Approach:

2a. Perform US and estimate uterine volumes and arterial resistance. Use descriptive statistics to compare values to controls in the same age group.

2b. Perform MRI and describe changes in each parameter among cases between the pre- and post-treatment timepoints. Assess changes in: size of the uterus from baseline, junctional zone anatomy, endometrial thickness, cervical length, myometrial thickness, T2 signal of the myometrium (normalized for skeletal muscle signal acting as an internal control), and enhancement features.

Enrollment

22 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Female
  2. Less than 40 years old "at the time of pelvic radiation"
  3. ≥ 18 and < 45 years of age "at time of enrollment"
  4. Treated with PRT at UCH
  5. Pelvic MRI taken before the pelvic radiation

Exclusion criteria

  1. Patients who underwent hysterectomy for treatment of a primary gynecologic malignancy
  2. Patients that are currently pregnant

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

22 participants in 2 patient groups

Cases undergone PRT
Active Comparator group
Description:
Patients (or their legal guardians) who opt for participating in this pilot study will be consented and enrolled in the study. Patients will then be scheduled for a single study visit at the University of Colorado Hospital (UCH) that includes: 1. Pregnancy test 2. Pelvic MRI without and with contrast (if patient consents to contrast) 3. Transabdominal pelvic ultrasound using standard B-mode and Doppler US, SWE 4. Optional transvaginal ultrasound using standard B-mode and Doppler US, SWE
Treatment:
Diagnostic Test: MRI, SWE, and US evaluation
Controls
Sham Comparator group
Description:
Controls (or their legal guardians) who opt for participating in this pilot study will be consented and enrolled in the study. Patients will then be scheduled for a single study visit at the University of Colorado Hospital (UCH) that includes: 1. Pregnancy test 2. Pelvic MRI without and with contrast (if patient consents to contrast) 3. Transabdominal pelvic ultrasound using standard B-mode and Doppler US, SWE 4. Optional transvaginal ultrasound using standard B-mode and Doppler US, SWE
Treatment:
Diagnostic Test: MRI, SWE, and US evaluation

Trial contacts and locations

1

Loading...

Central trial contact

Jocelyn Phipers, NP; Guluzar Turan, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems